

For Immediate Release

CyGenics in International Cancer Therapy Collaboration

International effort to develop new cancer treatment

Key Points:

- CyGenics part of new international collaborative effort for new cancer treatments involving leading science and industry groups from four countries
- Validation of CyGenics' T cell technology platform and further evidences CyGenics strategy of partnering and leveraging of existing assets
- CyGenics' collaborative research activities expands from Australia, Singapore, and USA to now include Europe

2nd February 2006 – Leading cell therapy company CyGenics Ltd. (ASX: CYN) announced that it will be part of a new international collaborative effort to develop new treatments for cancer. This will be done via the novel approach of developing and mobilising immune cells outside the human body.

Called PACRIMA, the project brings together leading organisations from four countries: Division Haemato-Oncology of University Hospital Maastricht (AZM), the Netherlands, CyGenics, Maia-Scientific NV of Belgium, Pharmacell BV of the Netherlands, and a leading stem cell research institute in Japan. The partners anticipate that the majority of the project will be funded by grants and have applied for funding from a number of sources including EUREKA, a pan-European initiative to foster European research and development.

Current cancer therapies successfully treat 50% of patients, often with serious side effects. The body's T cells and natural killer (NK) cells need to be mobilised against the cancer. This mobilisation is done by dendritic cells, another specialised cell of the immune system. These cells patrol the body in search of foreign cells such as cancer cells. Once detected, the dendritic cells absorb part of the foreign cells' structure, and pass this information on to T cells and NK cells, which are then mobilized to kill the cells.

The PACRIMA Project seeks to stimulate the patient's own immune system to fight against cancer. PACRIMA seeks to explore whether CyGenics' patented three-dimensional cell culture platform, the Cytomatrix, is a suitable platform for growing antigen specific T cells (T cells activated for a specific disease by dendritic cells) and NK cells, and whether these cells are suitable for therapeutic use. CyGenics, from its pool of stem cells that have been donated for research, will also supply some of the stem cells from which all these cells – dendritic cells, T cells, NK cells – may be derived. If successful, this project would be a significant improvement over the current T cell culture platform.



“It is one of our main objectives to initiate a Centre of Excellence for Cell Therapy in Maastricht,” said René Lardenoije, CEO of PharmaCell. “This R&D project with key players in the cell therapy arena will be very important for us to reach our goal. We are extremely pleased with this broad international cooperation. Bringing science and industry together in order to develop novel products and therapies is the way to build a strong future for Life Science here in Limburg.”

“PACRIMA serves as a further validation of the efficacy of CyGenics’ technology as a growth platform for various cell cultures,” said Steven Fang, Group CEO of CyGenics. “This follows upon other collaborations such as with Johns Hopkins University, announced just two months’ ago. These collaborations are fully in line with our corporate goal of realising the commercial potential of our technologies without the associated risks. The PACRIMA Project holds out the possibility of a truly elegant cure for many indications, without side effects, and has the potential of replacing many current treatment regimes.”

About CyGenics

CyGenics is a cell therapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates four subsidiaries: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

General Inquiries

Steven Fang, CEO, CyGenics Ltd Mob: +61 (0)400 933 243 Email: steven.fang@CyGenics.com	Ian Brown, COO, CyGenics Ltd Mob: +61 (0)438 565 212 Email: ian.brown@cygenics.com
--	--

Media Inquiries

Rebecca Piercy, Buchan Consulting Ph: +61 (0)3 9866 4722 Mob: +61 (0)422 916 422 Email: rpiercy@bcg.com.au	Ronald Hee, CyGenics Ltd Ph: +65 6238 0808 Mob: +65 9061 9098 Email: ronald.hee@cygenics.com
---	--